FHL-501

FHL-501 is a **preclinical peptide therapeutic** being developed by Forest Hills Business Association for neurodegenerative and acute neurologic indications including Alzheimer's Disease, Parkinson's Disease, Stroke, and Lewy Body Dementia. Available company and contextual information indicates that FHL-501 is designed to inhibit the **NF-kappaB inflammatory pathway**, with reported preclinical effects including reduction of brain inflammation, protection of dopaminergic neurons, and promotion of lysosomal biogenesis-mediated clearance of pathogenic molecules. Molecular target-level disclosure remains limited, but the program is positioned as a neuroprotective and anti-inflammatory peptide candidate within the company's neurodegeneration pipeline.